Jennifer Michaelson - Sep 20, 2021 Form 4 Insider Report for Cullinan Oncology, Inc. (CGEM)

Role
Chief Development Officer, Biologics
Signature
/s/ Jeffrey Trigilio, Attorney-in-Fact
Stock symbol
CGEM
Transactions as of
Sep 20, 2021
Transactions value $
-$80,848
Form type
4
Date filed
9/21/2021, 04:30 PM
Previous filing
Aug 26, 2021
Next filing
Oct 20, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CGEM Common Stock Options Exercise $17.2K +4K +17.46% $4.30 26.9K Sep 20, 2021 Direct
transaction CGEM Common Stock Sale -$77.9K -3.2K -11.89% $24.34 23.7K Sep 20, 2021 Direct F1, F2
transaction CGEM Common Stock Sale -$20.2K -800 -3.37% $25.20 22.9K Sep 20, 2021 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CGEM Stock Option (Right to Buy) Options Exercise $0 -4K -1.77% $0.00 222K Sep 20, 2021 Common Stock 4K $4.30 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 29, 2021.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.92 to $24.89. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.95 to $25.48. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 25% of the shares vested on July 4, 2020, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

Remarks:

Chief Development Officer, Biologics